Want to buy a pain ther­a­py? Nek­tar lays out a PhI­II sales pitch

Nek­tar Ther­a­peu­tics has a late-stage pain drug to sell to some­one. And this morn­ing the San Fran­cis­co-based biotech — which has been build­ing a fo­cus on on­col­o­gy — added a Phase III read­out show­ing NK­TR-181’s abil­i­ty to hand­i­ly beat out a place­bo in treat­ing chron­ic pain.

The key at­trac­tion to this drug, though, is Nek­tar’s $NK­TR billing this ther­a­py as the first mu-opi­oid ag­o­nist to lessen the pain with­out trig­ger­ing the eu­pho­ria that launched the opi­oid epi­dem­ic in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.